Biolase Announces Inaugural Clinical Excellence Forum

Event will focus on optimizing integration of lasers into clinical practice with recognized leaders from all dental specialties and academia

FOOTHILL RANCH, Calif., June 9, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers is proud to host its first annual meeting of leading dental laser experts on June 10, 2022 and June 11, 2022 at the Avenue of the Arts in Costa Mesa, CA.

The event gathers over 20 renowned clinicians from the general dentistry community, Endodontics, Periodontics, Pediatrics, Hygiene and academia. This group is among the leading voices in clinical care currently utilizing dental lasers and the gathering will promote faster integration of laser technology into clinical practice and increased acceptance of lasers in dentistry globally.

“We are excited to bring leading dentists and hygienists together to discuss current treatments and accelerating the pace of laser adoption” commented John Beaver, President and Chief Executive Officer. “It is rewarding to see our mission of advancing dentistry being embraced by so many in the industry, and we look forward to working with this group of distinguished clinicians to enact further positive change in patient standard of care.”

Sessions include new models for training, immersive education, dental team and patient communication as well as ideation and new ways to bring laser technology to the forefront of patient care.

For more information on the event visit:


BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at, Facebook at, Twitter at, Instagram at, and LinkedIn at

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the anticipated roll out of new go-to-market sales strategies, the Company’s efforts to achieve its goal of becoming EBITDA positive. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the “Risk Factors” section of BIOLASE’s annual reports filed on Form 10-K with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:


Michael Polyviou / Todd Kehrli

(732) 933-2754

[email protected] / [email protected]

Cision View original content to download multimedia:



Open chat
thank you for contacting us, for more information,
please chat